SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-19-119748
Filing Date
2019-04-25
Accepted
2019-04-25 16:31:03
Documents
10
Period of Report
2019-06-10
Effectiveness Date
2019-04-25

Document Format Files

Seq Description Document Type Size
1 DEF 14A d713345ddef14a.htm DEF 14A 546283
2 GRAPHIC g713345g28m21.jpg GRAPHIC 115509
3 GRAPHIC g713345g32f32.jpg GRAPHIC 141557
4 GRAPHIC g713345g36g42.jpg GRAPHIC 28251
5 GRAPHIC g713345g39a84.jpg GRAPHIC 236571
6 GRAPHIC g713345g78t93.jpg GRAPHIC 172070
7 GRAPHIC g713345g92f71.jpg GRAPHIC 104610
8 GRAPHIC g713345g97o73.jpg GRAPHIC 58228
9 GRAPHIC g713345page011.jpg GRAPHIC 282258
10 GRAPHIC g713345page012.jpg GRAPHIC 147128
  Complete submission text file 0001193125-19-119748.txt   2320379
Mailing Address 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND CA 94804
Business Address 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND CA 94804 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

IRS No.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-30171 | Film No.: 19767862
SIC: 2836 Biological Products, (No Diagnostic Substances)